Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 9/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21451648 | 0.89 | PTPN1 (0.36) | KDM4EPOLBBDKRB1 | |
| SCHEMBL19730054 | 0.77 | JAK2 (0.49) | KDM4EBDKRB1 | |
| SCHEMBL31500888 | 0.77 | JAK2 (0.49) | KDM4EBDKRB1 | |
| SCHEMBL21451895 | 0.70 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL21451653 | 0.70 | KMT2A (0.33) | KDM4EMAPTALDH1A1 | |
| SCHEMBL19730051 | 0.69 | JAK2 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL21451933 | 0.68 | HDAC6 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL20546008 | 0.66 | KDM4E (0.58) | KDM4EPOLBATMBDKRB1ALDH1A1 | |
| SCHEMBL17386398 | 0.65 | SLC6A3 (0.61) | KDM4EPOLBATMSLC6A3SLC6A4 | |
| SCHEMBL69464 | 0.64 | SLC6A3 (0.67) | KDM4EPOLBATMSLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918645-B2 | Substituted tricyclic heterocyclic compounds and use thereof | LIFEARC (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20190307763-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF | LIFEARC (GB) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918645-B2 | Substituted tricyclic heterocyclic compounds and use thereof | MAPT, TTBK1, TNK2 | KDM4E 3760/4885POLB 1872/4885ATM 442/4885 |
| US-20190307763-A1 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF | MAPT, NNMT, TKFC | KDM4E 3987/4885POLB 1251/4885ATM 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.